Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival

The completeness of tumor removal during surgery is dependent on the surgeon’s ability to differentiate tumor from normal tissue using subjective criteria that are not easily quantifiable. A way to objectively assess tumor margins during surgery in patients would be of great value. We have developed a method to visualize tumors during surgery using activatable cell-penetrating peptides (ACPPs), in which the fluorescently labeled, polycationic cell-penetrating peptide (CPP) is coupled via a cleavable linker to a neutralizing peptide. Upon exposure to proteases characteristic of tumor tissue, the linker is cleaved, dissociating the inhibitory peptide and allowing the CPP to bind to and enter tumor cells. In mice, xenografts stably transfected with green fluorescent protein show colocalization with the Cy5-labeled ACPPs. In the same mouse models, Cy5-labeled free ACPPs and ACPPs conjugated to dendrimers (ACPPDs) delineate the margin between tumor and adjacent tissue, resulting in improved precision of tumor resection. Surgery guided by ACPPD resulted in fewer residual cancer cells left in the animal after surgery as measured by Alu PCR. A single injection of ACPPD dually labeled with Cy5 and gadolinium chelates enabled preoperative whole-body tumor detection by MRI, intraoperative guidance by real-time fluorescence, intraoperative histological analysis of margin status by fluorescence, and postoperative MRI tumor quantification. Animals whose tumors were resected with ACPPD guidance had better long-term tumor-free survival and overall survival than animals whose tumors were resected with traditional bright-field illumination only.

[1]  Phil Quirke,et al.  What is the role for the circumferential margin in the modern treatment of rectal cancer? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Kavanagh,et al.  Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. , 2007, The Journal of urology.

[3]  R Weissleder,et al.  Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. , 2001, Radiology.

[4]  Jörg-Christian Tonn,et al.  Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. , 2008, Clinical neurosurgery.

[5]  Diana B Petitti,et al.  Bmc Ear, Nose and Throat Disorders Open Access Surgical Margins and Survival after Head and Neck Cancer Surgery , 2022 .

[6]  Kristjan Plaetzer,et al.  ALA and its clinical impact, from bench to bedside , 2008, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[7]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[8]  Sharmeela Kaushal,et al.  Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer , 2008, Journal of Gastrointestinal Surgery.

[9]  Hisataka Kobayashi,et al.  Multicolor in vivo targeted imaging to guide real‐time surgery of HER2‐positive micrometastases in a two‐tumor coincident model of ovarian cancer , 2009, Cancer science.

[10]  M. Soloway,et al.  Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[11]  Roger Y Tsien,et al.  In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[12]  S. Singletary Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. , 2002, American journal of surgery.

[13]  R. Weissleder,et al.  Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. , 2002, Radiology.

[14]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  John V Frangioni,et al.  New technologies for human cancer imaging. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Boturyn,et al.  In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors , 2007, Molecular Cancer.

[17]  Utilization and outcomes of minimally invasive radical prostatectomy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[19]  Merrick I Ross,et al.  Positive surgical margins and ipsilateral breast tumor recurrence predict disease‐specific survival after breast‐conserving therapy , 2003, Cancer.

[20]  Andries Zijlstra,et al.  A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. , 2002, Cancer research.

[21]  Sharmeela Kaushal,et al.  Imaging of Primary and Metastatic Pancreatic Cancer Using a Fluorophore-Conjugated Anti-CA19-9 Antibody for Surgical Navigation , 2008, World Journal of Surgery.

[22]  E. Frei,et al.  INTRAOPERATIVE FLUORESCENCE STAINING OF MALIGNANT BRAIN TUMORS USING 5‐AMINOFLUORESCEIN‐LABELED ALBUMIN , 2009, Neurosurgery.

[23]  Roger Y Tsien,et al.  Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[24]  R. Snijder,et al.  Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin. , 1998, The Annals of thoracic surgery.